Pure Global
NCT05917145

Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors

Phase 0/I Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors
Mayo Clinic·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Glioblastoma
Drug/Device/Intervention
WSD0628
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Rochester, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Sep 15, 2023
End date
Oct 15, 2028
Enrollment
67 participants
Primary outcome

Determine the maximum tolerated dose of WSD0628 in combination with radiation therapy for patients with recurrent high-grade glioma.,Determine the recommended phase 2 dose of WSD0628 in combination with radiation therapy for patients with recurrent high-grade glioma.

Summary

The purpose of this study is to test WSD0628 in combination with radiation therapy for
 recurrent brain tumors.

ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05917145
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05917145 through Pure Global AI's free database. This Phase 1 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 67 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.